As there is an increase of MBDB abuse, which is listed as a controlled substance in most countries, and an increase of requests for pharmacokinetic and analytical data (7), particular attention must be focused on the screening stage of the drug.
Immunoassay Responses of MBDB To the Editor:
The psychoactive effects ofN-methyl-l-(3,4-methylenedioxyphenyl)-2-butanamine (MBDB) have been described as different from those of typical hallucinogens and generally similar to those of 3,4-methylenedioxymethamphetamine (MDMA) with less euphoria (1) . Although the action of MDMA and MBDB at serotonin neurons are of comparable potency, that of MBDB is considerably weaker at dopamine neurons (2) , which is consistent with the presence of an o~-ethyl group on the structure of MBDB that dramatically attenuates the ability of the compound to interact with the dopamine carrier. In fact, a comparison of the relative toxic effects of MDMA and MBDB Methamphetamine II (Abbott, Wiesbaden, Germany); radioimmunoassay (RIA) Methamphetamine (DPC, Los Angeles, CA); and two noninstrumental immunoassays, RapiTest (Princeton Biomeditech, Princeton, N J) AccuSign Amphetamine and Accusign Methamphetamine 500. These kits were chosen as they exhibit, according to their manufacturers, the best cross-reactivity for MDMA in comparison with the others of the same technology. Calibrators and positive cutoff were as follows: d-methamphetamine at 1000 ng/mL (EMIT), d-amphetamine at 300 ng/rnL (FPIA), methamphetamine at 500 ng/mL (RIA), d-amphetamine at 1000 ng/mL (RapiTest Amphetamine), and d-rnethamphetamine at 500 ng/mL (RapiTest Methamphetamine 500). Concentrations, as measured with GC-MS, were in the ranges of 44-18577 and 11-543 ng/mL for MBDB and BDB, respectively. No other substance from the amphetamine derivatives group was identified in urine by GC-MS. Results are presented in Table I and clearly demonstrate that commercial immunoassays are not able to detect MBDB and its metabolite in usual specimens. A positive response can only be observed at very high concentrations. The noninstrumental immunoassay RapiTest was definitively unable to recognize MBDB. Based on the results, FPIA seems to be better able to detect the target drug, probably because of a higher cross-reactivity for MBDB and a lower positive cutoff than the other kits.
In the case of a controlled 100-rag administration (6), MBDB was detected in urine for 4, 8, and 4 h after drug intake using EMIT, FPIA, and RIA, respectively, and GC-MS detected MBDB for 36 h after administration.
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